Esophageal and/or Cardia Cancer, Melanoma, UC – HLX18

|

A Study to InvA Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors

NCT07518043

Sponsors: Henlius

This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety and immunogenicity of HLX18 and OPDIVO® in patients with resected esophageal or gastroesophageal junction cancer (EC/GEJC), melanoma (MEL), or urothelial carcinoma (UC).